|
|
Volumn 10, Issue 1, 2003, Pages 6-12
|
|
Amended report from the NAMS Advisory Panel on postmenopausal hormone therapy
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CONJUGATED ESTROGEN;
ESTROGEN;
GESTAGEN;
MEDROXYPROGESTERONE ACETATE;
ADULT;
AGED;
CANCER RISK;
CARDIOVASCULAR RISK;
CLINICAL PRACTICE;
CLINICAL TRIAL;
COGNITIVE DEFECT;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG INDICATION;
FEMALE;
HORMONAL THERAPY;
HUMAN;
LONG TERM CARE;
MAJOR CLINICAL STUDY;
MEDICAL RESEARCH;
MEDICAL SOCIETY;
MULTICENTER STUDY;
OSTEOPOROSIS;
POSTMENOPAUSE;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
RISK BENEFIT ANALYSIS;
SYMPTOMATOLOGY;
CONFERENCE PAPER;
CONSENSUS DEVELOPMENT;
DECISION MAKING;
ESTROGEN THERAPY;
MIDDLE AGED;
PRACTICE GUIDELINE;
RISK ASSESSMENT;
STANDARD;
UNITED STATES;
AGED;
DECISION MAKING;
ESTROGEN REPLACEMENT THERAPY;
FEMALE;
HUMANS;
MIDDLE AGED;
PHYSICIAN'S PRACTICE PATTERNS;
POSTMENOPAUSE;
RANDOMIZED CONTROLLED TRIALS;
RISK ASSESSMENT;
SOCIETIES, MEDICAL;
UNITED STATES;
|
|
EID: 0013026405
PISSN: 10723714
EISSN: None
Source Type: Journal
DOI: 10.1097/00042192-200310010-00003 Document Type: Review |
|
Times cited : (72)
|
|
References (0)
|